EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, ADR Biomedical Holdings's Enterprise Value is 円7,061.22 Mil.
ADR Biomedical Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was 円-784.77 Mil. Therefore, ADR Biomedical Holdings's EV-to-FCF for today is -9.00.
The historical rank and industry rank for ADR Biomedical Holdings's EV-to-FCF or its related term are showing as below:
TSE:3750'
s EV-to-FCF Range Over the Past 10 Years
Min: -199.55 Med: -7.96 Max: 35.61
Current: -9.11
During the past 13 years, the highest EV-to-FCF of ADR Biomedical Holdings was 35.61. The lowest was -199.55. And the median was -7.96.
TSE:3750's EV-to-FCF is ranked worse than 100% of 330
companies
in the Biotechnology industry
Industry Median: 16.33
vs TSE:3750: -9.11
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ADR Biomedical Holdings's PE Ratio (TTM) for today is calculated as:
ADR Biomedical Holdings's share price for today is 円805.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ADR Biomedical Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was 円-44.460.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:3750 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, ADR Biomedical Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADR Biomedical Holdings EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADR Biomedical Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where ADR Biomedical Holdings's EV-to-FCF falls into.
ADR Biomedical Holdings's current Enterprise Value is 円7,061.22 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ADR Biomedical Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was 円-784.77 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADR Biomedical Holdings (TSE:3750) has a EV-to-FCF of -9.00 as of Jul. 09, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on ADR Biomedical Holdings and its competitors. According to the industry distribution chart, ADR Biomedical Holdings ranks #999999 out of 330 companies in the Biotechnology industry.
Is ADR Biomedical Holdings' EV-to-FCF too high?
ADR Biomedical Holdings' current EV-to-FCF is -9.00. Based on the distribution chart, ADR Biomedical Holdings ranks #999999 out of 330 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ADR Biomedical Holdings has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ADR Biomedical Holdings' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ADR Biomedical Holdings ranks #999999 out of 330 companies for EV-to-FCF. This places ADR Biomedical Holdings in the lower half of its industry. The industry median EV-to-FCF is 16.33. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.33, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on ADR Biomedical Holdings and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADR Biomedical Holdings's current EV-to-FCF is -9.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADR Biomedical Holdings stock overvalued right now?
Based on GuruFocus' analysis, ADR Biomedical Holdings (TSE:3750) is currently considered Significantly Overvalued. The stock's GF Value™ is 円40.42, compared to a current price of 円805.00 — trading 1891.6% above its estimated fair value. The current EV-to-FCF is -9.00. ADR Biomedical Holdings' overall GF Score™ is 30/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For ADR Biomedical Holdings (TSE:3750), the current EV-to-FCF is -9.00 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADR Biomedical Holdings (TSE:3750) Overvalued in 2026?
Based on GuruFocus' analysis, ADR Biomedical Holdings stock appears to be overvalued.
The current stock price of 円805.00 is trading 1891.6% above its estimated GF Value™ of 円40.42.
GuruFocus considers ADR Biomedical Holdings to be Significantly Overvalued.
Key valuation signals for TSE:3750:
EV-to-FCF: -9.00
GF Value™: 円40.42 vs. price of 円805.00 (1891.6% above fair value)
No single metric tells the full story. See the TSE:3750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADR120S Inc developing a new clinical approach to cell therapy to provide medical care to patients by providing medical care that responds to unmet medical needs based on its regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.
30GF Score
Get the complete analysis for TSE:3750
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3750 has been successfully added to your 
